title: Venlafaxine and neuropathic pain.
abstract: The possible mechanisms involved in the antinociceptive effect of venlafaxine (VFX), a selective serotonin and noradrenaline reuptake inhibitor, after a single administration and chronic treatment were investigated in a diabetic neuropathic pain (DNP) model. VFX produced a significant antihyperalgesic effect after a single and repeated administration. This effect was reversed by pretreatment with yohimbine (a relatively selective α(2)-adrenergic antagonist) and p-chloroamphetamine (a neurotoxin which destroys serotonergic neurons). Conversely, naloxone (a nonselective opioid antagonist) did not reverse the effect of VFX in a DNP model. It is concluded that both noradrenergic and serotonergic mechanisms participate in the antinociceptive effect of VFX in the DNP model. However, the noradrenergic mechanism probably plays a more important role.
authors.affiliation: Department of Pharmacodynamics, Medical University of Warsaw, Warsaw, Poland. kcegielska@wum.edu.pl
authors.forename: Krystyna
authors.initials: K
authors.lastname: Cegielska-Perun
authors.forename: Magdalena
authors.initials: M
authors.lastname: Bujalska-Zadrożny
authors.forename: Jan
authors.initials: J
authors.lastname: Tatarkiewicz
authors.forename: Emilia
authors.initials: E
authors.lastname: Gąsińska
authors.forename: Helena Elżbieta
authors.initials: HE
authors.lastname: Makulska-Nowak
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D058669:Adrenergic alpha-2 Receptor Antagonists / Q000494:pharmacology; D000818:Animals; D003511:Cyclohexanols / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006930:Hyperalgesia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D017288:Pain Threshold / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D018490:Serotonin Agents / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D000069470:Venlafaxine Hydrochloride; D015016:Yohimbine / Q000494:pharmacology; D010133:p-Chloroamphetamine / Q000494:pharmacology
chemical_list: D018759:Adrenergic Uptake Inhibitors; D058669:Adrenergic alpha-2 Receptor Antagonists; D003511:Cyclohexanols; D009270:Naloxone; D009292:Narcotic Antagonists; D018490:Serotonin Agents; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride; D015016:Yohimbine; D010133:p-Chloroamphetamine